UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Nature communications, 2022-10, Vol.13 (1), p.6401-6401, Article 6401

2022

Link zum Volltext

Verfügbarkeit prüfen

Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome

Viruses, 2023-03, Vol.15 (3), p.701

2023

Link zum Volltext

Verfügbarkeit prüfen

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia

Frontiers in immunology, 2021-07, Vol.12, p.705974-705974

2021

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort

International journal of infectious diseases, 2022-07, Vol.120, p.187-195

2022

Link zum Volltext

Verfügbarkeit prüfen

Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome

Cancers, 2022-09, Vol.14 (19), p.4659

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

International journal of infectious diseases, 2024-02, Vol.139, p.69-77

2024

Link zum Volltext

Verfügbarkeit prüfen

Landscape of T‐cell repertoires with public COVID‐19‐associated T‐cell receptors in pre‐pandemic risk cohorts

Clinical & translational immunology, 2021, Vol.10 (9), p.e1340-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Nature immunology, 2021-01, Vol.22 (1), p.74

2021

Link zum Volltext

Verfügbarkeit prüfen

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

Nature (London), 2022-01, Vol.601 (7894), p.617-622

2022

Link zum Volltext

Verfügbarkeit prüfen

T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals

Science translational medicine, 2021-04, Vol.13 (590)

2021

Link zum Volltext

Verfügbarkeit prüfen

FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.TPS580-TPS580

2024

Link zum Volltext

Verfügbarkeit prüfen

Calpain-1 ablation partially rescues disease-associated hallmarks in models of Machado-Joseph disease

Human molecular genetics, 2020-04, Vol.29 (6), p.892-906

2020

Link zum Volltext

Verfügbarkeit prüfen

Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

Cancer discovery, 2021-08, Vol.11 (8), p.1982-1995

2021

Link zum Volltext

Verfügbarkeit prüfen

Tumorvakzinierung –Strategien und Timing

Der Internist (Berlin), 2021-09, Vol.62 (9), p.991-997

2021

Link zum Volltext

Verfügbarkeit prüfen

A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes

Molecular neurobiology, 2022-01, Vol.59 (1), p.495-522

2022

Link zum Volltext

Verfügbarkeit prüfen

Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination

Science immunology, 2022-12, Vol.7 (78), p.eadd3899

2022

Link zum Volltext

Verfügbarkeit prüfen

Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants

Clinical infectious diseases, 2023-02, Vol.76 (3), p.e240-e249

2023

Link zum Volltext

Verfügbarkeit prüfen

Tumorvakzinierung –Strategien und Timing

Gastroenterologe, 2021-07, Vol.16 (4), p.241-248

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3574: A Phase I trial of personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients under Bruton-Tyrosin-Kinase-inhibitor based regimes - Preclinical development and study design

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3574-3574

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3556: Immunopeptidomics-guided tumor antigen warehouse design and first clinical application of a personalized peptide vaccine for prostate cancer

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3556-3556

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3555: Immunopeptidomics-guided tumor antigen warehouse design for peptide-based immunotherapy in head and neck squamous cell carcinomas

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3555-3555

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT258: Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT258-CT258

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2008: The oncogenic fusion protein DNAJB1-PRKACA can be actively targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2008-2008

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(27)

Sprache

Englisch
(24)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(16)
Humans
(11)
Immunotherapy
(7)
Immunology
(6)
Lymphocytes
(6)
Lymphocytes T
(6)
Peptides
(6)
Coronaviruses
(5)
Covid-19
(5)
Oncology
(5)
Sars-Cov-2
(5)
Severe Acute Respiratory Syndrome Coronavirus 2
(5)
T Cells
(5)
Antibodies, Viral
(4)
Covid-19 - Prevention & Control
(4)
Covid-19 Vaccines
(4)
Health Aspects
(4)
Immune Response
(4)
Infectious Diseases
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia

Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort

Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

Landscape of T‐cell repertoires with public COVID‐19‐associated T‐cell receptors in pre‐pandemic risk cohorts

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals

FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

Calpain-1 ablation partially rescues disease-associated hallmarks in models of Machado-Joseph disease

Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

Tumorvakzinierung –Strategien und Timing

A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes

Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination

Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants

Tumorvakzinierung –Strategien und Timing

Abstract 3574: A Phase I trial of personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients under Bruton-Tyrosin-Kinase-inhibitor based regimes - Preclinical development and study design

Abstract 3556: Immunopeptidomics-guided tumor antigen warehouse design and first clinical application of a personalized peptide vaccine for prostate cancer

Abstract 3555: Immunopeptidomics-guided tumor antigen warehouse design for peptide-based immunotherapy in head and neck squamous cell carcinomas

Abstract CT258: Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency

Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells

Abstract 2008: The oncogenic fusion protein DNAJB1-PRKACA can be actively targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Suchergebnisse filtern